{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:48:23Z","timestamp":1774435703609,"version":"3.50.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"Supplement_5","license":[{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30DA011041"],"award-info":[{"award-number":["P30DA011041"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30DA040500"],"award-info":[{"award-number":["P30DA040500"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32DA007233-35"],"award-info":[{"award-number":["5T32DA007233-35"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Hepatitis C virus (HCV) remains endemic among people who use drugs (PWUD). Measures of HCV community viral load (CVL) and HCV care continuum outcomes may be valuable for ascertaining unmet treatment need and for HCV surveillance and control.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from patients in an opioid treatment program during 2013\u20132016 were used to (1) identify proportions of antibody and viral load (VL) tested, linked-to-care, and treated, in 2013\u20132014 and 2015\u20132016, and pre- and postimplementation of qualitative reflex VL testing; (2) calculate engaged-in-care HCV CVL and \u201cdocumented\u201d and \u201cestimated\u201d unmet treatment need; and (3) examine factors associated with linkage-to-HCV-care.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 11 267 patients, proportions of HCV antibody tested (52.5% in 2013\u20132014 vs 73.3% in 2015\u20132016), linked-to-HCV-care (15.7% vs 51.8%), and treated (12.0% vs 44.7%) all increased significantly. Hispanic ethnicity was associated with less linkage-to-care, and Manhattan residence was associated with improved linkage-to-care. The overall engaged-in-care HCV CVL was 4 351 079 copies\/mL (standard deviation = 7 149 888); local HCV CVLs varied by subgroup and geography. Documented and estimated unmet treatment need decreased but remained high.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>After qualitative reflex VL testing was implemented, care continuum outcomes improved, but gaps remained. High rates of unmet treatment need suggest that control of the HCV epidemic among PWUD will require expansion of HCV treatment coverage.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiz686","type":"journal-article","created":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T12:08:09Z","timestamp":1577189289000},"page":"S335-S345","source":"Crossref","is-referenced-by-count":13,"title":["Hepatitis C Virus (HCV) Care Continuum Outcomes and HCV Community Viral Loads Among Patients in an Opioid Treatment Program"],"prefix":"10.1093","volume":"222","author":[{"given":"Ashly E","family":"Jordan","sequence":"first","affiliation":[{"name":"Graduate School of Public Health and Health Policy, City University of New York, New York, New York, USA"},{"name":"Center for Drug Use and HIV Research (multi-institutional), New York, New York, USA"},{"name":"Behavioral Science Training Program in Drug Abuse Research, New York University, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles M","family":"Cleland","sequence":"additional","affiliation":[{"name":"Center for Drug Use and HIV Research (multi-institutional), New York, New York, USA"},{"name":"Division of Biostatistics, Department of Population Health, New York University School of Medicine, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce R","family":"Schackman","sequence":"additional","affiliation":[{"name":"Department of Healthcare Policy & Research, Weill Cornell Medicine, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Wyka","sequence":"additional","affiliation":[{"name":"Graduate School of Public Health and Health Policy, City University of New York, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C","family":"Perlman","sequence":"additional","affiliation":[{"name":"Center for Drug Use and HIV Research (multi-institutional), New York, New York, USA"},{"name":"Division of Infectious Diseases, Mount Sinai Beth Israel, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Nash","sequence":"additional","affiliation":[{"name":"Graduate School of Public Health and Health Policy, City University of New York, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,9,2]]},"reference":[{"key":"2020101904544917300_CIT0001","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.drugpo.2017.07.021","article-title":"High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic","volume":"47","author":"Norton","year":"2017","journal-title":"Int J Drug Policy"},{"key":"2020101904544917300_CIT0002","volume-title":"Working","author":"New York City Department of Health and Mental Hygiene","year":"2018"},{"key":"2020101904544917300_CIT0003","doi-asserted-by":"crossref","first-page":"e101554","DOI":"10.1371\/journal.pone.0101554","article-title":"The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis","volume":"9","author":"Yehia","year":"2014","journal-title":"PLoS One"},{"key":"2020101904544917300_CIT0004","doi-asserted-by":"crossref","first-page":"e97317","DOI":"10.1371\/journal.pone.0097317","article-title":"The hepatitis C cascade of care: identifying priorities to improve clinical outcomes","volume":"9","author":"Linas","year":"2014","journal-title":"PLoS One"},{"key":"2020101904544917300_CIT0005","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy048","article-title":"Hepatitis C treatment outcomes for people who inject drugs treated in an accessible care program located at a syringe service program","volume":"5","author":"Eckhardt","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2020101904544917300_CIT0006","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews","volume":"378","author":"Nelson","year":"2011","journal-title":"Lancet"},{"key":"2020101904544917300_CIT0007","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","article-title":"Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014","volume":"108","author":"Zibbell","year":"2018","journal-title":"Am J Public Health"},{"key":"2020101904544917300_CIT0008","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.drugalcdep.2015.03.039","article-title":"Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006\u20132013","volume":"152","author":"Jordan","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"2020101904544917300_CIT0009","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0140-6736(10)60742-8","article-title":"Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed","volume":"376","author":"Degenhardt","year":"2010","journal-title":"Lancet"},{"key":"2020101904544917300_CIT0010","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/01.aids.0000192066.86410.8c","article-title":"Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990\u20132001","volume":"19","author":"Des Jarlais","year":"2005","journal-title":"AIDS"},{"key":"2020101904544917300_CIT0011","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/add.12125","article-title":"Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction?","volume":"108","author":"de Vos","year":"2013","journal-title":"Addiction"},{"key":"2020101904544917300_CIT0012","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1111\/add.12682","article-title":"The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users","volume":"109","author":"Nolan","year":"2014","journal-title":"Addiction"},{"key":"2020101904544917300_CIT0013","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1111\/j.1360-0443.2011.03515.x","article-title":"The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence","volume":"106","author":"Turner","year":"2011","journal-title":"Addiction"},{"key":"2020101904544917300_CIT0014","volume-title":"European Monitoring Centre for Drugs and Drug Addiction Prevention and control of infectious diseases among people who inject drugs ECDC and EMCDDA guidance","author":"European Centre for Disease Prevention and Control","year":"2011"},{"key":"2020101904544917300_CIT0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugpo.2013.07.001","article-title":"Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness","volume":"25","author":"MacArthur","year":"2014","journal-title":"Int J Drug Policy"},{"key":"2020101904544917300_CIT0016","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/add.14012","article-title":"Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis","volume":"113","author":"Platt","year":"2018","journal-title":"Addiction"},{"key":"2020101904544917300_CIT0017","doi-asserted-by":"crossref","first-page":"e103345","DOI":"10.1371\/journal.pone.0103345","article-title":"Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention","volume":"9","author":"Wiessing","year":"2014","journal-title":"PLoS One"},{"key":"2020101904544917300_CIT0018","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1360-0443.2009.02888.x","article-title":"Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews","volume":"105","author":"Palmateer","year":"2010","journal-title":"Addiction"},{"key":"2020101904544917300_CIT0019","author":"Centers for Disease Control and Prevention","year":"2011"},{"key":"2020101904544917300_CIT0020","doi-asserted-by":"crossref","first-page":"e11068","DOI":"10.1371\/journal.pone.0011068","article-title":"Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco","volume":"5","author":"Das","year":"2010","journal-title":"PLoS One"},{"key":"2020101904544917300_CIT0021","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1097\/QAI.0b013e31828ed2e4","article-title":"Measuring the unknown: calculating community viral load among HIV-infected MSM unaware of their HIV status in San Francisco from National HIV Behavioral Surveillance, 2004\u20132011","volume":"63","author":"Das","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020101904544917300_CIT0022","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1097\/QAD.0b013e328360f619","article-title":"Disparities in community viral load among HIV-infected persons in New York City","volume":"27","author":"Laraque","year":"2013","journal-title":"AIDS"},{"key":"2020101904544917300_CIT0023","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S2352-3018(16)00019-9","article-title":"Community viral load, antiretroviral therapy coverage, and HIV incidence in India: a cross-sectional, comparative study","volume":"3","author":"Solomon","year":"2016","journal-title":"Lancet HIV"},{"key":"2020101904544917300_CIT0024","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1016\/S2352-3018(16)00036-9","article-title":"Community viral load as an index of HIV transmission potential","volume":"3","author":"Herbeck","year":"2016","journal-title":"Lancet HIV"},{"key":"2020101904544917300_CIT0025","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1086\/497131","article-title":"Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study","volume":"41","author":"Yazdanpanah","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020101904544917300_CIT0026","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejogrb.2015.09.009","article-title":"Risk factors for vertical transmission of hepatitis C virus: a single center experience with 710 HCV-infected mothers","volume":"194","author":"Garcia-Tejedor","year":"2015","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2020101904544917300_CIT0027","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/00365540510032105","article-title":"Mother to child transmission of hepatitis C virus: rate of infection and risk factors","volume":"37","author":"Syriopoulou","year":"2005","journal-title":"Scand J Infect Dis"},{"key":"2020101904544917300_CIT0028","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/hep.27966","article-title":"Cost-effectiveness of strategies for testing current hepatitis C virus infection","volume":"62","author":"Chapko","year":"2015","journal-title":"Hepatology"},{"key":"2020101904544917300_CIT0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13696998.2017.1369983","article-title":"Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting","volume":"21","author":"J\u00fclicher","year":"2018","journal-title":"J Med Econ"},{"key":"2020101904544917300_CIT0030","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3389\/fpubh.2017.00348","article-title":"Patterns and gaps identified in a systematic review of the hepatitis C virus care continuum in studies among people who use drugs","volume":"5","author":"Jordan","year":"2017","journal-title":"Front Public Health"},{"key":"2020101904544917300_CIT0031","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.2105\/AJPH.2013.301827","article-title":"Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study","volume":"104","author":"Frimpong","year":"2014","journal-title":"Am J Public Health"},{"key":"2020101904544917300_CIT0032","first-page":"351","article-title":"Implementation and evaluation of a multicomponent quality improvement intervention to improve efficiency of hepatitis C screening and diagnosis","volume":"40","author":"Hirsch","year":"2014","journal-title":"Jt Comm J Qual Patient Saf"},{"key":"2020101904544917300_CIT0033","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","volume":"67","author":"AASLD-IDSA HCV Guidance Panel","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020101904544917300_CIT0034","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.amjmed.2013.01.031","article-title":"Half a diagnosis: gap in confirming infection among hepatitis C antibody-positive patients","volume":"126","author":"McGibbon","year":"2013","journal-title":"Am J Med"},{"key":"2020101904544917300_CIT0035","first-page":"362","article-title":"Testing for HCV infection: an update of guidance for clinicians and laboratorians","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020101904544917300_CIT0036","article-title":"Refocusing hepatitis C prevention through geographic viral load analysis","volume-title":"Online J Public Health Inform","author":"Arnold","year":"2018"},{"key":"2020101904544917300_CIT0037","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.2105\/AJPH.2012.301129","article-title":"Missed opportunities for hepatitis C testing in opioid treatment programs","volume":"103","author":"Frimpong","year":"2013","journal-title":"Am J Public Health"},{"key":"2020101904544917300_CIT0038","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13722-018-0111-7","article-title":"Under one roof: identification, evaluation, and treatment of chronic hepatitis C in addiction care","volume":"13","author":"Martin","year":"2018","journal-title":"Addict Sci Clin Pract"},{"key":"2020101904544917300_CIT0039","first-page":"296","article-title":"Conceptualizing care continua: lessons from HIV, hepatitis C virus, tuberculosis and implications for the development of improved care and prevention continua","volume":"4","author":"Perlman","year":"2016","journal-title":"Front Public Health"},{"key":"2020101904544917300_CIT0040","doi-asserted-by":"crossref","first-page":"19395","DOI":"10.7448\/IAS.18.1.19395","article-title":"The HIV care cascade: models, measures and moving forward","volume":"18","author":"MacCarthy","year":"2015","journal-title":"J Int AIDS Soc"},{"key":"2020101904544917300_CIT0041","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1186\/s12879-016-1807-5","article-title":"Spontaneous viral clearance of hepatitis C virus (HCV) infection among people who inject drugs (PWID) and HIV-positive men who have sex with men (HIV+ MSM): a systematic review and meta-analysis","volume":"16","author":"Smith","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2020101904544917300_CIT0042","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies","volume":"13","author":"Micallef","year":"2006","journal-title":"J Viral Hepat"},{"key":"2020101904544917300_CIT0043","author":"New York City Department of Health","year":"2006"},{"key":"2020101904544917300_CIT0044","doi-asserted-by":"crossref","first-page":"e0199174","DOI":"10.1371\/journal.pone.0199174","article-title":"Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era","volume":"13","author":"Zuckerman","year":"2018","journal-title":"PLoS One"},{"key":"2020101904544917300_CIT0045","volume-title":"Released 2019. IBM SPSS Statistics for Windows, Version 24.0","author":"IBM Corp"},{"key":"2020101904544917300_CIT0046","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2019"},{"key":"2020101904544917300_CIT0047","doi-asserted-by":"crossref","first-page":"e0194799","DOI":"10.1371\/journal.pone.0194799","article-title":"Potential geographic \u201chotspots\u201d for drug-injection related transmission of HIV and HCV and for initiation into injecting drug use in New York City, 2011\u20132015, with implications for the current opioid epidemic in the US","volume":"13","author":"Des Jarlais","year":"2018","journal-title":"PLoS One"},{"key":"2020101904544917300_CIT0048","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.drugalcdep.2018.07.034","article-title":"Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000\u20132017: protective effects of non-injecting drug use","volume":"92","author":"Des Jarlais","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"2020101904544917300_CIT0049","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/hiv.12219","article-title":"Impact of defined clinical population and missing data on temporal trends in HIV viral load estimation within a health care system","volume":"16","author":"Edelman","year":"2015","journal-title":"HIV Med"},{"key":"2020101904544917300_CIT0050","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/QAI.0b013e31829cef18","article-title":"The effect of churn on \u201ccommunity viral load\u201d in a well-defined regional population","volume":"64","author":"Krentz","year":"2013","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/222\/Supplement_5\/S335\/33940798\/jiz686.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/222\/Supplement_5\/S335\/33940798\/jiz686.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T10:29:58Z","timestamp":1603103398000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/222\/Supplement_5\/S335\/5900607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,2]]},"references-count":50,"journal-issue":{"issue":"Supplement_5","published-online":{"date-parts":[[2020,9,2]]},"published-print":{"date-parts":[[2020,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiz686","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10,1]]},"published":{"date-parts":[[2020,9,2]]}}}